Skip to main content

Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.

Publication ,  Journal Article
Peyser, B; Perry, EP; Singh, K; Gill, RD; Mehan, MR; Haga, SB; Musty, MD; Milazzo, NA; Savard, D; Li, Y-J; Trujilio, G; Voora, D
Published in: Circ Genom Precis Med
September 2018

BACKGROUND: Outcomes of tailoring statin-type based on solute carrier organic anion transporterfamily member 1B1 ( SLCO1B1)pharmacogenetic toxicity information on patient, provider, and pharmacological outcomes are unknown. METHODS: The trial randomized 159 patients not taking statins because of prior statin myalgia 1:1 to receiving SLCO1B1 GIST (Genotype Informed Statin Therapy) versus usual care (UC) and followed for up to 8 months. The UC arm received their SLCO1B1 results post-trial. The primary outcome was statin adherence using the Morisky Medication Adherence Scale, which was assessed in those patients who reinitiated statins. Secondary outcomes assessed in all participants included statin reinitiation and LDLc (low-density lipoprotein cholesterol), within and post-trial. Using commercial laboratory data, serial LDLc were compared between 1907 patients receiving SLCO1B1 testing and propensity-matched, untested controls. RESULTS: Trial participants were 25% SLCO1B1*5 carriers. Statin adherence was similar between arms (Morisky Medication Adherence Scale in GIST versus UC, 6.8±1.5 versus 6.9±1.6, P=0.96). GIST led to more new statin prescriptions (55.4% versus 38.0%, P=0.04) and lower LDLc at 3 months (131.9±42.0 versus 144.4±43.0 mg/dL; P=0.048) with similar magnitude at 8 months (128.6±37.9 versus 141.0±44.4; P=0.12). SLCO1B1*5 carriers exhibited a greater drop in LDLc with GIST versus UC (interaction P=0.048). Post-trial, LDLc decreased in UC participants who crossed over to GIST compared with those allocated to GIST (-14.9±37.8 versus +9.0±37.3 mg/dL, P=0.03). Patients tested for SLCO1B1 though a commercial laboratory had a greater LDLc decrease ( P=0.04) compared with controls. CONCLUSIONS: Delivery of SLCO1B1 pharmacogenetic testing that addresses statin myalgia improved statin reinitiation and LDLc but did not improve self-reported statin adherence. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01894230.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Genom Precis Med

DOI

EISSN

2574-8300

Publication Date

September 2018

Volume

11

Issue

9

Start / End Page

e002228

Location

United States

Related Subject Headings

  • Young Adult
  • Precision Medicine
  • Pharmacogenomic Testing
  • Outcome Assessment, Health Care
  • Middle Aged
  • Medication Adherence
  • Male
  • Liver-Specific Organic Anion Transporter 1
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Peyser, B., Perry, E. P., Singh, K., Gill, R. D., Mehan, M. R., Haga, S. B., … Voora, D. (2018). Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circ Genom Precis Med, 11(9), e002228. https://doi.org/10.1161/CIRCGEN.118.002228
Peyser, Bruce, Emily P. Perry, Kavisha Singh, Rosalynn D. Gill, Michael R. Mehan, Susanne B. Haga, Michael D. Musty, et al. “Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.Circ Genom Precis Med 11, no. 9 (September 2018): e002228. https://doi.org/10.1161/CIRCGEN.118.002228.
Peyser B, Perry EP, Singh K, Gill RD, Mehan MR, Haga SB, et al. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circ Genom Precis Med. 2018 Sep;11(9):e002228.
Peyser, Bruce, et al. “Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.Circ Genom Precis Med, vol. 11, no. 9, Sept. 2018, p. e002228. Pubmed, doi:10.1161/CIRCGEN.118.002228.
Peyser B, Perry EP, Singh K, Gill RD, Mehan MR, Haga SB, Musty MD, Milazzo NA, Savard D, Li Y-J, Trujilio G, Voora D. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circ Genom Precis Med. 2018 Sep;11(9):e002228.

Published In

Circ Genom Precis Med

DOI

EISSN

2574-8300

Publication Date

September 2018

Volume

11

Issue

9

Start / End Page

e002228

Location

United States

Related Subject Headings

  • Young Adult
  • Precision Medicine
  • Pharmacogenomic Testing
  • Outcome Assessment, Health Care
  • Middle Aged
  • Medication Adherence
  • Male
  • Liver-Specific Organic Anion Transporter 1
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans